ABSTRACT
Objective The severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) has caused a pandemic claiming more than 4 million lives worldwide. Overwhelming Coronavirus-Disease-2019 (COVID-19) respiratory failure placed tremendous demands on healthcare systems increasing the death toll. Cost-effective prognostic tools to characterize COVID-19 patients’ likely to progress to severe hypoxemic respiratory failure are still needed.
Design We conducted a retrospective cohort study to develop a model utilizing demographic and clinical data collected in the first 12-hours admission to explore associations with severe hypoxemic respiratory failure in unvaccinated and hospitalized COVID-19 patients.
Setting University based healthcare system including 6 hospitals located in the Galveston, Brazoria and Harris counties of Texas.
Participants Adult patients diagnosed with COVID-19 and admitted to one of six hospitals between March 19th and June 31st, 2020.
Primary outcome The primary outcome was defined as reaching a WHO ordinal scale between 6-9 at any time during admission, which corresponded to severe hypoxemic respiratory failure requiring high-flow oxygen supplementation or mechanical ventilation.
Results We included 329 participants in the model cohort and 62 (18.8%) met the primary outcome. Our multivariable regression model found that lactate dehydrogenase (OR 3.38 (95% CI 2.04-5.59)), qSOFA score (OR: 2.24 (95% CI 1.22-4.12)), neutrophil to lymphocyte ratio (OR:1.08 (95% CI 1.02-1.14)), age (OR: 1.04 (95% CI 1.02-1.07)), BMI (OR: 1.08 (95% CI1.03-1.13)), oxygen saturation or admission SpO2 (OR: 0.91 (95% CI 0.83-0.99)), and admission date (OR: 0.99 (95% CI 0.98-0.99)). The final model showed an area under curve (AUC) of 0.85. The sensitivity analysis and point of influence analysis did not reveal inconsistencies.
Conclusions Our study demonstrated that a combination of accessible demographic and clinical information provide a powerful predictive tool to identify subjects with CoVID-19 likely to progress to severe hypoxemic respiratory failure.
STRENGTHS
⍰ Our study utilized objective and measurable demographic and clinical information regularly available in healthcare settings even among patients unable to communicate.
⍰ Our primary outcome corresponds to WHO ordinal score which would allow compare our results to other studies and in other settings.
⍰ Our model could serve as an effective point of service tool during early admission to assist in clinical management and allocation of resources to unvaccinated patients.
LIMITATIONS
⍰ Our study is a retrospective study of unvaccinated COVID19 patients, and validation of our prediction model in the rest of our study population is still needed.
⍰ In addition, testing our model in a more recent cohort after emergence of new SARS-CoV-2 variants will be needed to assess its robustness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No extramural funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by UTMB Institutional Review Board (20-0126) and the Texas Department of Criminal Justice (TDCJ) Institutional Review Board (#819-RM20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ An Exploratory Model for Respiratory Failure in Admitted SARS-CoV-2 Patients in Galveston, Texas, USA.
Data Availability
SAS Code and de-identified data will be published at Dryad, an online repository.
ABBREVIATIONS
- (SARS-CoV-2)
- Severe acute respiratory syndrome-Coronoavius-2
- (COVID-19)
- Coronaviurs-Disease-19
- (WHO)
- World Health Organization
- (CDC)
- Center of Disease Control and Prevention
- (UTMB)
- University of Texas Medical Branch
- (TDCJ)
- Texas Department of Criminal Justice
- (GCS)
- Glawgow coma scale
- (qSOFA)
- Quick Sequential Organ Failure Assessment
- (NLR)
- Neutrophil to lymphocyte ratio
- (LDH)
- Lactate Dehydrogenase
- (CRP)
- C-reactive protein
- (BMI)
- Body mass index
- (IQR)
- Interquartile range
- (SD)
- Standard deviation
- (AIC)
- Stepwise Akaike Information Criteria
- (GOF)
- Goodness of fit
- (ROC)
- Receiver operating characteristics curve
- (AUC)
- Area under the curve